References:
- Gisbert JP, Gonzalez-Lama Y, Mate J. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 2007; 13(5):629-638.
- Greenstein AJ, Sachar DB, Panday AK, Dikman SH, Meyers S, Heimann T, Gumaste V, Werther JL, Janowitz HD. Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients. Medicine (Baltimore) 1992; 71(5):261-270.
- Gonlusen G, Akgun H, Ertan A, Olivero J, Truong LD. Renal failure and nephrocalcinosis associated with oral sodium phosphate bowel cleansing: clinical patterns and renal biopsy findings. Arch Pathol Lab Med 2006; 130(1):101-106.
- Markowitz GS, Stokes MB, Radhakrishnan J, D'Agati VD. Acute phosphate nephropathy following oral sodium phosphate bowel purgative: an underrecognized cause of chronic renal failure. J Am Soc Nephrol 2005; 16(11):3389-3396.
- Brunelli SM, Lewis JD, Gupta M, Latif SM, Weiner MG, Feldman HI. Risk of kidney injury following oral phosphosoda bowel preparations. J Am Soc Nephrol 2007; 18(12):3199-3205.
- Beloosesky Y, Grinblat J, Weiss A, Grosman B, Gafter U, Chagnac A. Electrolyte disorders following oral sodium phosphate administration for bowel cleansing in elderly patients. Arch Intern Med 2003; 163(7):803-808.
- Gonlusen G, Akgun H, Ertan A, Olivero J, Truong LD. Renal failure and nephrocalcinosis associated with oral sodium phosphate bowel cleansing: clinical patterns and renal biopsy findings. Arch Pathol Lab Med 2006; 130(1):101-106.
- Berndt T, Kumar R. Phosphatonins and the regulation of phosphate homeostasis. Annu Rev Physiol 2007; 69:341-59.:341-359.
- Berndt T, Thomas LF, Craig TA, Sommer S, Li X, Bergstralh EJ, Kumar R. Evidence for a signaling axis by which intestinal phosphate rapidly modulates renal phosphate reabsorption. Proc Natl Acad Sci U S A 2007; 104(26):11085-11090.
- Izzedine H, Camous L, Bourry E, Azar N, Leblond V, Deray G. Make your diagnosis. Multiple myeloma-associated with spurious hyperphosphatemia. Kidney Int 2007; 72(8):1035-1036.
|
<%
else
if currentID = 1 or currentID = 11 then%>
Question 1) - What are the possible causes of acute kidney injury or chronic kidney disease in a patient with Crohn’s disease?
(Only ONE answer is correct)
|
| > |
a) Administration of 5-aminosalicylic acid. |
| > |
b) Renal amyloidosis. |
| > |
c) Dehydration, infection, septicemia in severe courses. |
| > |
d) Phosphate overload following oral sodium phosphate bowel cleansing. |
| > |
e) All of the above. |
<%if currentID = 11 then%>
<%
if Answer1 = RightAnswer1 then
Response.Write " Answer to question n. 1 is right!
"
else
Response.Write " Answer to question n. 1 is wrong!
"
Response.Write " The right answer is the checked one! "
end if
%>
The administration of 5-aminosalicylic acid may be associated with the development of interstitial nephritis in patients with colitis (1). Rash, fever, eosinophilia, and eosinophiluria are typical signs several days or weeks after the administration of a causative drug. However, the present patient had not received mesalazine or sulfasalazine and signs of hypersensitivity reactions were absent.
In long-lasting, chronic relapsing Crohn’s disease systemic amyloidosis may develop based on the chronic inflammatory state (SAA-amyloidosis) (2).
Of course, severe or fatal bursts of the disease may end up with acute kidney injury due to dehydration, infection and septicemia.
The administration of oral sodium phosphate bowel cleansing (oral sodium phosphosoda, OPS) is an increasingly recognized cause for acute hyperphosphatemia with several potentially fatal sequelae (please refer to question 2) (3,4). Acute kidney failure may be among them. In the outpatient setting, it is clearly recommended to use oral sodium phosphate bowel cleansing only with high amounts of oral fluid intake. National drug safety guidelines recommend the intake of additional 1700 ml of clear liquid / water during the last 24 hrs prior to colonoscopy, if bowel preparation with two bottles of Fleet® Phospho-soda is scheduled. Each 45 ml bottle of Fleet® Phospho-soda contains 24.4g Natriumdihydrogenphosphat-2H2O and 10.8 g Natriummonohydrogenphosphat-12H2O. OPS contain about approximately six times the average daily phosphate intake (5).
<%
newID = 2
else
newID = 11
%>
|
<%end if%>
 |
The clinical course of our patient was satisfactory. Renal function recovered to normal urinary output within four days. S-creatinine levels slowly decreased and were normal 3 months later. This complete remission is exceptional: In a large case series 4/21 patients developed ESRD and the remaining 17/21 recovered but all exhibited CKD after a mean of 17 months of follow-up.

Nephrocalcinosis was no longer detectable on ultrasonography three months later.
A recent case control study could not prove an increase in the risk of developing renal failure in patients prepared for endoscopy with OPS (5). However, renal failure was defined as an increase in S-creatinine within 6 months after endoscopy. Our case report highlights the fact that even severe renal failure requiring dialysis may resolve completely and that within 3 months S-creatinine levels may decrease to normal levels. Therefore, a prospective short-term plus long-term follow-up study is required in order to assess the true dimension of the problem.